Exclusive Summary

• - All patents expired and market fully genericized; FDA-approved status enables reliance registrations and faster entry into many markets.
• - Multi-indication hospital demand across anesthesia/PONV, oncology antiemesis and premedication, emergency/ICU, and respiratory exacerbations; ~330M surgeries/year underpin steady volume.
• - Listed on the WHO Essential Medicines List and strongly recommended by major guidelines; 4–8 mg IV is standard in perioperative and chemotherapy antiemesis protocols.
• - While competition is crowded, quality varies; FDA approval plus Zone IV stability provides compliance and registration advantages in tropical and reliance markets.
• - China GMP line with restartable supply supports cost-competitive tenders and distributors to scale volume rapidly.